Literature DB >> 8333835

Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.

S M de Morais1, H Schweikl, J Blaisdell, J A Goldstein.   

Abstract

There is a genetic polymorphism in humans in the metabolism of S-mephenytoin which has been suggested to be mediated by either CYP2C18 or CYP2C9. We have isolated genomic clones for CYP2C9 and CYP2C18 from the liver of an individual phenotyped in vitro as an extensive metabolizer of S-mephenytoin. Analysis of the genes reveals nine coding exons spanning approximately 55 kb. The intron-exon organization was similar to that of other members of the CYP2C subfamily. Analysis of 2200 bp of 5' upstream sequence for CYP2C9 and 1300 bp 5' upstream sequence for CYP2C18 reveals canonical TATA boxes situated 57 bp upstream from the first codon, multiple consensus sequences for glucocorticoid regulatory elements, and identification of a 15 base sequence with high homology to a 5'-flanking sequence responsible for barbiturate-inducible expression of P450BM-3 in Bacillus megaterium. The upstream region for CYP2C9 was highly homologous (75%) to that of human CYP2C8 through most of the 2200 bp sequenced, but the upstream region of CYP2C18 was similar to CYP2C8 and CYP2C9 for only the first 200 bases. The availability of the sequences of the upstream regions and intron-exon junctions of CYP2C9 and CYP2C18 will allow future analysis of these genes in humans which differ in their ability to metabolize S-mephenytoin and other drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333835     DOI: 10.1006/bbrc.1993.1803

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver.

Authors:  P G Zaphiropoulos
Journal:  Nucleic Acids Res       Date:  1999-07-01       Impact factor: 16.971

Review 2.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Allele and genotype frequencies of CYP2C9 in a Korean population.

Authors:  Jung-Woo Bae; Hyun-Kyung Kim; Ji-Hong Kim; Sang-In Yang; Mi-Jeong Kim; Choon-Gon Jang; Young-Seo Park; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

4.  Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis.

Authors:  P G Zaphiropoulos
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

Review 5.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

Review 7.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

8.  Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver.

Authors:  Vivaswath S Ayyar; Siddharth Sukumaran; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2018-08-07       Impact factor: 4.030

Review 9.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.